The US Supreme Court has temporarily restored broad access to the abortion pill mifepristone, a decision that maintains one of the primary methods of abortion provision across the United States. The order, signed by Justice Samuel Alito on Monday, allows individuals seeking abortions to continue obtaining the pill at pharmacies or through mail-order services, effectively blocking a lower court ruling that had threatened to significantly restrict its availability.
This latest development means that for now, the regulatory landscape surrounding mifepristone reverts to its status before the recent legal challenges. The pill, which is used in combination with another medication, misoprostol, for medical abortions, has been at the centre of an escalating legal battle following the overturning of Roe v. Wade in 2022.
The previous ruling, which the Supreme Court has now paused, sought to revert the drug's availability to conditions set before 2016. This would have included requiring in-person doctor visits for prescriptions and prohibiting mail-order distribution, significantly impacting access, particularly in rural areas or states with limited abortion providers.
Mifepristone is a crucial component of medical abortions, which account for more than half of all abortions in the US. The drug works by blocking progesterone, a hormone necessary for pregnancy to continue. Its efficacy and safety have been widely affirmed by major medical organisations.
In the UK, medical abortion is a common and safe procedure. NHS guidelines and NICE recommendations support the use of mifepristone in combination with misoprostol for early medical abortion, typically up to 10 weeks of pregnancy, under the care of a healthcare professional. Readers in the UK seeking information on abortion should consult their GP or local NHS services.